GSK Positive on Outlook as HIV Drugs, Vaccines Spur Growth

GSK Plc reported better-than-expected profit and raised its estimates for revenue at two key divisions in a report that offered some respite after recent setbacks.

The UK drugmaker’s best-selling shingles shot Shingrix as well as specialty medicines including drugs for asthma, HIV and cancer underpinned the improved outlook. The shares climbed as much as 2% in early London trading before paring gains.